EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Update on biologic and small molecules treatments in pediatric allergic diseases

Herman T den Dekker iD, Amandine Divaret Chauveau iD, Benoit Sterling iD, Stéphanie Coopman iD, R Sharon Chinthrajah iD, Stéphanie Lejeune iD, Dorothea Holter iD, Thomas Eiwegger iD, Stéphanie Mallet, Mariëlle W Pijnenburg iD, Antoine Deschildre iD

Pediatric Allergy and Immunology · 2026

DOI: 10.1111/pai.70454 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pediatric Allergy and Immunology, 2026. Verfasst von Herman T den Dekker und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics/Pediatric Respiratory Medicine and Allergology, Erasmus MC - Sophia Children's Hospital, University Medical Center Rotterdam…. Hauptthemen laut MEDLINE: Hypersensitivity, Anti-Allergic Agents, Biological Products. Die Arbeit nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biologics have revolutionized the treatment of severe allergic diseases in children that cannot be controlled by conventional treatments. These diseases are commonly driven by dysregulation of immune response, often driven by Type 2 pathways. By targeting them, biologics have the potential for treating one or more allergic diseases. Thus, a “treat to target” strategy is now prioritized, allowing treatment of allergic diseases in a personalized approach. The pioneer anti‐IgE monoclonal antibody, omalizumab, was initially indicated for the treatment of moderate to severe allergic asthma and is now indicated for chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps (CRSwNP), and food allergy (FA), highlighting the ability of biologics to target multiple allergic diseases. Other biologics have been developed in asthma and other allergic diseases, including mepolizumab (anti‐IL5), benralizumab (anti‐IL5 receptor), dupilumab (anti–IL‐4 receptor α), and more recently tezepelumab (anti‐TSLP). Clinical trials in children and/or teenagers have demonstrated their efficacy and safety, confirmed by real‐life studies, in asthma, atopic dermatitis (AD), CSU, and more recently in eosinophilic esophagitis (EoE) and FA. Beyond biologics, small molecules such as Janus kinase inhibitors target other key pathways and have already been approved in AD, with ongoing clinical trials in other allergic diseases. In the pediatric specific context, these treatments raise questions, particularly regarding the choice of biologics and the goals. In the long term, the sustained efficacy, safety and impact on the natural history of allergic diseases need to be further studied. The aim of this review is to discuss the most recent data in the use of biologics and small molecules in pediatric allergic diseases and to highlight the remaining gaps in knowledge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypersensitivityAnti-Allergic AgentsBiological ProductsHumansChildAntibodies, Monoclonal, HumanizedOmalizumabAsthmaFood HypersensitivityAdolescentAntibodies, Monoclonal

Stichwörter der Autor:innen

atopic dermatitisbiologicschildrenchronic spontaneous urticariaeosinophilic esophagitisfood allergysevere asthmasmall molecules

Substanzen

Anti-Allergic AgentsBiological ProductsAntibodies, Monoclonal, HumanizedOmalizumabmepolizumabdupilumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Pediatrics/Pediatric Respiratory Medicine and Allergology, Erasmus MC - Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Pediatric Allergy Unit, Children's Hospital, University Hospital of Nancy, Vandoeuvre les Nancy, France.
  • UR 3450 DevAH, Campus Brabois Santé, University of Lorraine, Vandoeuvre les Nancy, France.
  • Aix-Marseille Univ, APHM, Hôpital Timone, Service de Dermatologie-Vénéréologie, Marseille, France.
  • Department of Pediatric Gastroenterology Hepatology and Nutrition, Centre Hospitalier Universitaire Lille, Reference Center for Congenital Oesophageal Anomalies, Lille, France.
  • Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, California, USA.

ORCID-Profile: Herman T den Dekker, Amandine Divaret Chauveau, Benoit Sterling, Stéphanie Coopman, R Sharon Chinthrajah, Stéphanie Lejeune, Dorothea Holter, Thomas Eiwegger, Mariëlle W Pijnenburg, Antoine Deschildre

Zitieren

APA

den Dekker, H. T., Chauveau, A. D., Sterling, B., Coopman, S., Chinthrajah, R. S., Lejeune, S., Holter, D., Eiwegger, T., Mallet, S., Pijnenburg, M. W., & Deschildre, A. (2026). Update on biologic and small molecules treatments in pediatric allergic diseases. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70454

Vancouver

den Dekker HT, Chauveau AD, Sterling B, Coopman S, Chinthrajah RS, Lejeune S, et al. Update on biologic and small molecules treatments in pediatric allergic diseases. Pediatric Allergy and Immunology. 2026. doi:10.1111/pai.70454

BibTeX
@article{denDekker2026,
  author = {den Dekker, Herman T and Chauveau, Amandine Divaret and Sterling, Benoit and Coopman, Stéphanie and Chinthrajah, R Sharon and Lejeune, Stéphanie and Holter, Dorothea and Eiwegger, Thomas and Mallet, Stéphanie and Pijnenburg, Mariëlle W and Deschildre, Antoine},
  title = {Update on biologic and small molecules treatments in pediatric allergic diseases},
  journal = {Pediatric Allergy and Immunology},
  year = {2026},
  doi = {10.1111/pai.70454}
}
Kostenlos starten →